Drug therapy for atrial fibrillation.
Atrial fibrillation is the most frequently diagnosed arrhythmia. Prevalence increases with age, and the overall incidence is expected to increase as the population continues to age. Choice of pharmacologic therapy for atrial fibrillation depends on whether or not the goal of treatment is maintaining sinus rhythm or tolerating atrial fibrillation with adequate control of ventricular rates. Many new antiarrhythmic drugs are currently being tested in clinical trials. Drugs that target remodeling and inflammation have shown potential in prevention of atrial fibrillation, or as adjunctive therapy.
Conway
Emily L
EL
Lankenau Hospital, Division of Cardiovascular Diseases, Main Line Heart Center, Suite 556, Medical Office Building East, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.
Musco
Simone
S
Kowey
Peter R
PR
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents